Cargando…
Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
The primary objectives of this study were to determine the maximum tolerated dose (MTD) of paclitaxel administered by 3‐h infusion to patients with solid tumors, and to characterize the pharmacokinetics of a 3‐h infusion in comparison with those of a 24‐h infusion. Twenty‐seven patients each receive...
Autores principales: | Tamura, Tomohide, Sasaki, Yasutsuna, Nishiwaki, Yutaka, Saijo, Nagahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920663/ https://www.ncbi.nlm.nih.gov/pubmed/8636011 http://dx.doi.org/10.1111/j.1349-7006.1995.tb03316.x |
Ejemplares similares
-
Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994) -
Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001) -
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion.
por: Kunitoh, H., et al.
Publicado: (1998) -
Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989) -
Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs
por: Ohtsu, Atsushi, et al.
Publicado: (1989)